IFF Pharma Showcases Next-Gen Excipients at CPHI Japan 2025
IFF Pharma Solutions is set to showcase its latest cutting-edge excipient technologies at CPHI Japan 2025, reinforcing its commitment to revolutionizing drug formulation and patient-centered pharmaceutical innovations. The event will take place at Tokyo Big Sight East Halls 4-6 from April 9-11, where the IFF Pharma Solutions team will highlight advancements in oral disintegrating tablets (ODTs), controlled-release formulations, and novel complex formulations at booth 5K-21.
Elevating Drug Delivery through Innovation
“IFF Pharma Solutions is committed to redefining drug delivery through material science innovation,” stated Frank Zhao, Commercial Leader, IFF Pharma Solutions, Asia Pacific. “At CPHI Japan, we will showcase technologies designed to elevate patient outcomes while streamlining pharmaceutical production.”
IFF Pharma Solutions, as a global leader in excipient technologies, continues to push the boundaries of pharmaceutical formulation with novel solutions that enhance drug efficacy, stability, and bioavailability. The company’s latest innovations focus on improving patient adherence, extending drug release profiles, and ensuring regulatory compliance with the evolving global standards for excipients.
Breakthroughs in Oral Disintegrating Tablets (ODTs)
The demand for ODTs is growing rapidly, particularly for pediatric and geriatric patients who require easy-to-administer, fast-dissolving formulations. A key challenge in ODT formulation is achieving rapid disintegration while maintaining tablet stability. IFF Pharma Solutions addresses this need with:
- Ac-Di-Sol®: A premier super disintegrant, Ac-Di-Sol® ensures rapid tablet disintegration, offering equivalent performance to polyvinylpolypyrrolidone (PVPP). By enhancing dissolution speed, it improves patient compliance and supports the growing ODT market.
Advanced Controlled-Release Technologies
IFF Pharma Solutions will also showcase its portfolio of excipients designed to optimize controlled-release (CR) drug formulations, ensuring steady drug delivery over extended periods. This segment includes:
- METHOCEL™ Hydroxypropyl Methylcellulose (HPMC): A key component in controlled-release drug delivery, METHOCEL™ enables consistent and precise medication release, enhancing therapeutic efficacy and patient adherence through customizable formulations.
- ETHOCEL™ Ethylcellulose: A water-resistant polymer used for barrier coatings in modified-release tablets, ETHOCEL™ ensures targeted drug release and taste masking, a crucial requirement for pediatric and geriatric populations.
- POLYOX™ Polyethylene Oxide: Known for its high-swelling properties, POLYOX™ supports osmotic pump technology and abuse-deterrent formulations, allowing for the creation of sophisticated drug delivery systems that enhance patient safety and efficacy.
Addressing Nitrosamine Contamination with Low-Nitrite Solutions
Nitrosamines, classified as probable human carcinogens, have raised global regulatory concerns in recent years, prompting stricter guidelines for pharmaceutical formulations. IFF Pharma Solutions has proactively expanded its low-nitrite excipient portfolio to address this issue:
- Avicel® PH LN: A low-nitrite microcrystalline cellulose (MCC) that reduces the risk of nitrosamine formation in oral solid dosage forms. This innovative excipient ensures compliance with Japan’s stringent regulatory standards and aligns with global safety requirements.
- Low-Nitrite METHOCEL™: IFF Pharma Solutions has introduced a low-nitrite version of its flagship METHOCEL™ product, further enhancing the safety profile of controlled-release formulations while mitigating nitrosamine contamination risks.
A Holistic Approach to Pharmaceutical Innovation
In addition to its cutting-edge excipient solutions, IFF Pharma Solutions is dedicated to offering customized formulation support to its pharmaceutical partners. The company’s expertise extends beyond material science, providing:
- Customized Formulation Development: Tailored solutions to optimize excipient compatibility and functionality in different drug formulations.
- Regulatory and Compliance Guidance: Support to navigate complex global regulatory landscapes, ensuring adherence to evolving pharmaceutical standards.
- Sustainability and Green Chemistry Initiatives: A commitment to sustainable excipient manufacturing, reducing environmental impact while maintaining high-quality standards.
The Future of Pharmaceutical Excipients
As the pharmaceutical industry continues to evolve, IFF Pharma Solutions remains at the forefront of excipient innovation. The company is actively exploring new avenues, including:
- Nanotechnology-Based Drug Delivery: Researching nanocarrier systems to enhance solubility and bioavailability of poorly water-soluble drugs.
- Biodegradable Polymers for Drug Formulations: Developing excipients that align with eco-friendly pharmaceutical manufacturing trends.
- Personalized Medicine Applications: Advancing excipient technology to support precision drug delivery tailored to individual patient needs.
